Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 14, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | China, Chinese Coronavirus, Wuhan, Wuhan Coronavirus, china coronavirus, coronavirus
The coronavirus continues to dominate the news, with the disease finally getting treated. In America, a patient has been successfully treated with an Ebola drug from Gilead. This drug is also being used in China on patients with mass production set to start soon.
Pharmaceutical companies have also seen some staff shakeups, with GlaxoSmithKline set to cut 720 jobs in Belgium while Sanofi has axed five members of its executive committee.
10. Highest fatalities from coronavirus recorded in a single day due to new classifications
The coronavirus outbreak reached its deadliest day since it began in December.
9. NICE plans to use broader range of data in guidance
The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.
8. Eli Lilly’s solanezumab fails at Phase 2/3 in early-onset Alzheimer’s disease
In another blow to Alzheimer’s research, it has emerged that a study investigating Eli Lilly’s solanezumab in the treatment of early-onset Alzheimer’s disease failed to meet its primary endpoint.
7. Several European cases of coronavirus traced to ski resort in the Alps
Multiple European cases of coronavirus have been traced to a ski resort in the Alps, with a British man spread the disease to several others he came into contact with.
6. Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials
Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form of Alzheimer’s disease.
5. Sanofi axes four major players from its executive committee
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief Executive Officer Paul Hudson, who joined the company in September last year.
Patients regularly find value in participating in clinical trials, but many are not given the option by medical professionals and some were outwardly discouraged form taking part, says a new report from Patient Power, a media organisation providing “patient-powered journalism, information and opportunities.”
3. GSK to axe 720 positions at Belgian vaccine facility
GlaxoSmithKline has announced a cull of staff at its vaccine production site in Belgium, with 720 employees facing the axe.
2. Patient successfully treated for coronavirus in the US
Health officials in the US say they have successfully treated a man for coronavirus with an experimental drug.
1. Chinese company starts mass producing Gilead coronavirus drug
A drugmaker in China said it has started mass producing Gilead Sciences Ebola drug that has the potential to fight the coronavirus.
Related Content
AstraZeneca and Sanofi’s Beyfortus approved in China
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
Boan Biotech has announced that the first patient has been enrolled in its phase 3 …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …
